University Hospitals Coventry and Warwickshire NHS Trust

ALLOSOURCE ANNOUNCES FIRST PATIENT IMPLANTATION IN UNITED KINGDOM CLINICAL EVALUATION OF PROCHONDRIX CR CRYOPRESERVED OSTEOCHONDRAL ALLOGRAFT

Retrieved on: 
Tuesday, October 31, 2023
University Hospitals Coventry and Warwickshire NHS Trust, Cartilage, NHS trust, Research, Trust, Surgeon, University Hospitals Cleveland Medical Center, Chondrocyte, Knee, Patient

CENTENNIAL, Colo., Oct. 31, 2023 /PRNewswire/ -- AlloSource® , one of the United States leading innovators and manufacturers of cartilage for joint preservation, today announced the first patient implantation of ProChondrix® CR Cryopreserved Osteochondral Allograft in a United Kingdom (UK) independent evaluation.

Key Points: 
  • CENTENNIAL, Colo., Oct. 31, 2023 /PRNewswire/ -- AlloSource® , one of the United States leading innovators and manufacturers of cartilage for joint preservation, today announced the first patient implantation of ProChondrix® CR Cryopreserved Osteochondral Allograft in a United Kingdom (UK) independent evaluation.
  • The procedure was conducted by Dr. Nick Smith, D.O., a knee specialist orthopedic surgeon with University Hospitals Coventry and Warwickshire, NHS Trust.
  • "The operation went very well and the patient was discharged the same day with very little postoperative discomfort," said Dr. Nick Smith.
  • The purpose of the UK evaluation is to assess the clinical outcomes and complications of patients undergoing cartilage surgery using ProChondrix CR as part of standard clinical care without a comparator group.

ALLOSOURCE ANNOUNCES FIRST PATIENT IMPLANTATION IN UNITED KINGDOM CLINICAL EVALUATION OF PROCHONDRIX CR CRYOPRESERVED OSTEOCHONDRAL ALLOGRAFT

Retrieved on: 
Tuesday, October 31, 2023
University Hospitals Coventry and Warwickshire NHS Trust, Cartilage, NHS trust, Research, Trust, Surgeon, University Hospitals Cleveland Medical Center, Chondrocyte, Knee, Patient, Medical device

CENTENNIAL, Colo., Oct. 31, 2023 /PRNewswire/ -- AlloSource® , one of the United States leading innovators and manufacturers of cartilage for joint preservation, today announced the first patient implantation of ProChondrix® CR Cryopreserved Osteochondral Allograft in a United Kingdom (UK) independent evaluation.

Key Points: 
  • CENTENNIAL, Colo., Oct. 31, 2023 /PRNewswire/ -- AlloSource® , one of the United States leading innovators and manufacturers of cartilage for joint preservation, today announced the first patient implantation of ProChondrix® CR Cryopreserved Osteochondral Allograft in a United Kingdom (UK) independent evaluation.
  • The procedure was conducted by Dr. Nick Smith, D.O., a knee specialist orthopedic surgeon with University Hospitals Coventry and Warwickshire, NHS Trust.
  • "The operation went very well and the patient was discharged the same day..." said Dr. Nick Smith.
  • The purpose of the UK evaluation is to assess the clinical outcomes and complications of patients undergoing cartilage surgery using ProChondrix CR as part of standard clinical care without a comparator group.

Avanos Medical Supports New Interventional Procedure Recommendations from the UK's National Institute of Health and Care Excellence (NICE)

Retrieved on: 
Wednesday, June 28, 2023
Avanos, Arthritis, University Hospitals Coventry and Warwickshire NHS Trust, Quality of life, Trust, Hypoesthesia, Radiofrequency ablation, Pain, Avanos Medical, Patient, NHS trust, NHS, Radio frequency, Osteoarthritis, RFA, NICE, UHCW, National Institute for Health and Care Excellence, Pharmaceutical industry, Nursing

ALPHARETTA, Ga., June 28, 2023 /PRNewswire/ -- Avanos Medical supports the announcement today from the UK's National Institute for Health and Care Excellence (NICE) recommending the use of radiofrequency ablation (RFA) for the treatment of osteoarthritic knee pain.

Key Points: 
  • ALPHARETTA, Ga., June 28, 2023 /PRNewswire/ -- Avanos Medical supports the announcement today from the UK's National Institute for Health and Care Excellence (NICE) recommending the use of radiofrequency ablation (RFA) for the treatment of osteoarthritic knee pain.
  • The radiofrequency energy can be delivered as conventional radiofrequency, cooled radiofrequency or pulsed radiofrequency.
  • "We are extremely pleased with today's interventional procedure recommendation by NICE," commented Dieter Krines, Avanos Vice President & General Manager, Europe.
  • I hope this will now help to increase awareness of this innovative therapy leading to improved outcomes for many more patients."

Avanos Medical Supports New Interventional Procedure Recommendations from the UK's National Institute of Health and Care Excellence (NICE)

Retrieved on: 
Wednesday, June 28, 2023
Avanos, Arthritis, University Hospitals Coventry and Warwickshire NHS Trust, Quality of life, Trust, Hypoesthesia, Radiofrequency ablation, Pain, Avanos Medical, Patient, NHS trust, NHS, Radio frequency, Osteoarthritis, RFA, NICE, UHCW, National Institute for Health and Care Excellence, Pharmaceutical industry, Nursing

ALPHARETTA, Ga., June 28, 2023 /PRNewswire/ -- Avanos Medical supports the announcement today from the UK's National Institute for Health and Care Excellence (NICE) recommending the use of radiofrequency ablation (RFA) for the treatment of osteoarthritic knee pain.

Key Points: 
  • ALPHARETTA, Ga., June 28, 2023 /PRNewswire/ -- Avanos Medical supports the announcement today from the UK's National Institute for Health and Care Excellence (NICE) recommending the use of radiofrequency ablation (RFA) for the treatment of osteoarthritic knee pain.
  • The radiofrequency energy can be delivered as conventional radiofrequency, cooled radiofrequency or pulsed radiofrequency.
  • "We are extremely pleased with today's interventional procedure recommendation by NICE," commented Dieter Krines, Avanos Vice President & General Manager, Europe.
  • I hope this will now help to increase awareness of this innovative therapy leading to improved outcomes for many more patients."

Ibex Secures PathLAKE Contracts to Roll Out AI-based Cancer Diagnostics to UK Hospitals

Retrieved on: 
Tuesday, March 7, 2023
Trust, Hospital, Trust law, Prostate cancer, Diagnosis, Wales, Addenbrooke's Hospital, Artificial intelligence, Consultant, Innovate UK, Breast, Prostate, Woman, TEL, Nottingham University Hospitals NHS Trust, Cambridge University Hospitals NHS Foundation Trust, Cancer, Laboratory, University Hospitals Coventry and Warwickshire NHS Trust, Innovation, Pathology, University, AI, Oxford University Hospitals NHS Foundation Trust, Marie Cassidy, Digital pathology, Addenbrooke, Megaproject, Medical device, Medical imaging, Ibex, NHS Wales

TEL AVIV, Israel , March 7, 2023 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced the receipt of multiple contract awards from the PathLAKE consortium  to provide Artificial Intelligence (AI) solutions to support cancer diagnosis at 25 NHS Trusts.

Key Points: 
  • TEL AVIV, Israel , March 7, 2023 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced the receipt of multiple contract awards from the PathLAKE consortium  to provide Artificial Intelligence (AI) solutions to support cancer diagnosis at 25 NHS Trusts.
  • PathLAKE is a UK center of excellence consortium, founded by Innovate UK, that is delivering AI innovation in pathology across leading NHS Trusts and UK universities including Nottingham University Hospitals, University Hospitals Coventry & Warwickshire, and Oxford University Hospitals.
  • Cambridge University Hospitals is one of the Trusts to subsequently select Ibex to support its pathologists by augmenting diagnostic workflows with enhanced quality, accuracy and efficiency.
  • "We are extremely honored to be recognized by PathLAKE as the leading provider of AI solutions in pathology," said Richard Nicholson, Director of Sales, UK at Ibex.

Ibex Scoops Second Win of The UK Artificial Intelligence Award with Leading NHS Trusts

Retrieved on: 
Monday, March 6, 2023
North West Anglia NHS Foundation Trust, Social work, Trust, Hospital, Prostate cancer, University Hospitals Cleveland Medical Center, Diagnosis, Betsi Cadwaladr University Health Board, University of Nottingham, University, Artificial intelligence, TEL, Imperial College London, Deep learning, Nottingham University Hospitals NHS Trust, Patient, Cambridge University Hospitals NHS Foundation Trust, Cancer, NHS foundation trust, National Health Service, University Hospitals Coventry and Warwickshire NHS Trust, University Hospitals Birmingham NHS Foundation Trust, Breast cancer, Government, Pathology, Oxford University Press, Entrepreneurship, UK Health Security Agency, Doctor of Philosophy, Marie Cassidy, Nursing, University College London, NIHR, NHS, Pharmaceutical industry, Medical imaging, Ibex, Health, AI, Nature

TEL AVIV, Israel, March 6, 2023 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, University of Nottingham and a consortium of NHS Trusts, announced today they are winners of the UK Artificial Intelligence in Health and Care Award, enabling the deployment of Ibex's Galen™ Breast solution across five National Health Services (NHS) and delivering on their aligned missions of improving breast cancer diagnosis and lab efficiency.

Key Points: 
  • Galen Breast supports pathologists by providing AI-based tools and insights that help detect and grade different types of breast cancer.
  • The solution will be deployed at Nottingham University Hospitals, Cambridge University Hospitals, North West Anglia NHS Foundation Trust, Betsi Cadwaladr University Health Board and University Hospitals Birmingham.
  • Timely and accurate diagnosis can significantly impact breast cancer survival rates, making Ibex's solution a vital and welcome addition into NHS trusts."
  • "We are proud to receive this award from the NIHR and NHS, said Chaim Linhart, PhD, Co-Founder and Chief Technology Officer of Ibex Medical Analytics.

Fujifilm receives regulatory approval for its latest generation Endoscopic Ultrasound endoscope (EG-740UT) and achieves compatibility of its Ultrasound endoscope line-up with Fujifilm Healthcare's flagship ARIETTA Ultrasound system (ARIETTA 850 FF ENDO (*

Retrieved on: 
Wednesday, September 28, 2022
ENDO, Arietta, Gastrointestinal tract, Fine-needle aspiration, Efficiency, Esophagus, List of Medknow Publications academic journals, Duodenum, Sale, University Hospitals Coventry and Warwickshire NHS Trust, Acquisition, EUS, Health, Elasticity, Patient, Physician, Work Channel, Abdomen, Quality of life, Cell, Solution, Pathology, Diagnosis, Medical imaging, Hitachi, Color, RTE, Extrapyramidal system, Stomach, Endoscopy, Fujifilm, Ultrasound

Fujifilm has developed a new generation therapeutic linear array Ultrasound endoscope, the EG-740UT, designed for complex diagnostic and therapeutic endoscopic Ultrasound procedures.

Key Points: 
  • Fujifilm has developed a new generation therapeutic linear array Ultrasound endoscope, the EG-740UT, designed for complex diagnostic and therapeutic endoscopic Ultrasound procedures.
  • Endoscopic Ultrasound is widely used especially for the detailed examination and diagnosis of pancreatic and biliary lesions (*3).
  • Moreover, Interventional Endoscopic Ultrasound is becoming widely adopted for therapeutic applications involving the pancreatic and biliary anatomy.
  • By combining Fujifilm's latest generation EG-740UT Ultrasound endoscope with the ARIETTA 850, Fujifilm intends to provide outstanding Ultrasound image quality with advanced therapeutic capability.

Metrion Biosciences Expands Ion Channel Drug Discovery Service Capabilities and In-house Expertise

Retrieved on: 
Tuesday, December 7, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Penta, University Hospitals Coventry and Warwickshire NHS Trust, Future Attribute Screening Technology, Company, APC, Drug discovery, HTS, Research, Â, Shao Kahn, Cell biology, Immortalised cell line, Cardiac electrophysiology, University, Molecular Devices, Bachelor of Science, University of London, Doctor of Philosophy, Physiology, Electrophysiology, Television

Metrion Biosciences Limited (Metrion), the specialist ion channel contract research and drug discovery company, today announced it has expanded its capabilities and expertise through the addition of automated low volume liquid handling capability and 384-well electrophysiology and fluorescence-based high throughput screening (HTS) assay systems.

Key Points: 
  • Metrion Biosciences Limited (Metrion), the specialist ion channel contract research and drug discovery company, today announced it has expanded its capabilities and expertise through the addition of automated low volume liquid handling capability and 384-well electrophysiology and fluorescence-based high throughput screening (HTS) assay systems.
  • Dr Clark has over 20 years experience in drug discovery, 14 of which have been in ion channel contract research.
  • Metrions enhanced ion channel drug discovery service capabilities will include the introduction of additional automated low volume liquid handling capabilities, 384-well electrophysiology and fluorescence-based high HTS assay systems.
  • He also brings to Metrion extensive strategic drug discovery knowledge for ion channel targets across multiple therapeutic areas, and excellent client liaison skills.

VitalHub Increases Q2 2021 Revenue to $5.8M While Continuing to Improve on Financial Metrics Across the Business

Retrieved on: 
Tuesday, August 24, 2021
Company, Comment, East, Expansion, Growth, Interim, National Health Service, Acquisition, In Touch, Conversation, GLOBE, Hampshire Hospitals NHS Foundation Trust, University Hospitals Dorset NHS Foundation Trust, University Hospitals Coventry and Warwickshire NHS Trust, National Health Service (England), Consolidated, Warwickshire, Management, ARR, NHS, VHI, Conference, Q&A, Metropolitan Family Services, COVID-19, Income, EBITDA, Pharmaceutical industry, Mobile phone, Hospital

This represents a 46% growth in organic annual recurring revenue over and above the $8.8 million annual recurring revenue purchased through acquisitions.

Key Points: 
  • This represents a 46% growth in organic annual recurring revenue over and above the $8.8 million annual recurring revenue purchased through acquisitions.
  • The Company is approaching our target of 20% Adjusted EBITDA, with 18% Adjusted EBITDA reported in Q2 2021.
  • To register for the conference call please visit: VitalHub Q2 2021 Conference Call or https://bit.ly/VitalHubQ221 .
  • Gross profit as a percentage of revenue for Q2 2021 was 77% compared to 73% in Q2 2020.

Persica Pharmaceuticals has completed the first stage of its clinical trial on unique injectable PP353, to treat chronic lower back pain

Retrieved on: 
Thursday, August 19, 2021
Pharmacology, Quality of life, Adoption, National Institute for Health Research, Pharmacokinetics, Disability, Coventry, Human, Research, Royal Preston Hospital, Teaching hospital, Committee, Low back pain, University Hospitals Coventry and Warwickshire NHS Trust, NIHR, Clinical trial, Persica, Safety, Complex, Patient, National Institute, Injection, Medication, Pharmaceutical industry

Persica Pharmaceuticals has completed the first stage of its clinical trial on unique injectable PP353, to treat chronic lower back pain

Key Points: 
  • Persica Pharmaceuticals has completed the first stage of its clinical trial on unique injectable PP353, to treat chronic lower back pain
    Uniquely for a First in Human CLBP trial there is already clinical proof of concept for the approach.
  • London, UK, 19 August 2021 Persica Pharmaceuticals Ltd, a clinical stage pharmaceutical company developing PP353, a unique injectable antibiotic, to treat chronic low back pain (CLBP) associated with bone oedema (Modic 1) today announces that it has successfully completed the first stage of a Phase Ib clinical trial to evaluate the safety, tolerability and pharmacokinetics of PP353.
  • PP353 is a sustained release formulation of an antibiotic to treat the chronic disc infection, which is designed for intradiscal injection under image guidance.
  • The Committee recommended that efficacy of a two-dose regimen of PP353 be tested in the next stage of clinical evaluation.